AstraZeneca said it agreed on a provision with the Advanced Defense Research Projects Direction (DARPA) and the Advanced Biomedical Research and Development Agency (BARDA) of the United States to support development projects. monoclonal antibody treatments against SARS-CoV-2 virus that cause COVID-19 disease. However, it did not disclose the financial terms of these agreements.
Many health experts believe that antibody-based treatments have great potential for the treatment of COVID-19 in the context of promising vaccine candidates in the SARS-CoV-2 virus room. now in the world.
Astra Zeneca said it has licensed six promising vaccines from Vanderbilt University in Nashville, Tennessee after evaluating more than 1,500 potential monoclonal antibodies. Two of these six promising proteins will be tested as a combination treatment for COVID-19 prevention.
Antibodies are made in the body to combat the invasion of bacteria and viruses. Monoclonal antibodies mimic natural antibodies and can be separated and produced in large quantities to treat patients.